DIFFERENCES IN JAK2V617F POSITIVE PATIENTS WITH AND WITHOUT THROMBOSIS ACCORDING TO DIAGNOSIS, AGE, SEX AND V617F ALLELE BURDEN
Author(s): ,
Ivana Horvat
Affiliations:
Department of Laboratory Diagnostics,University Hospital Center Zagreb,Zagreb,Croatia
,
Margareta Radic Antolic
Affiliations:
Department of Laboratory Diagnostics,University Hospital Center Zagreb,Zagreb,Croatia
,
Pavle Roncevic
Affiliations:
Department of Hematology,University Hospital Center Zagreb,Zagreb,Croatia
,
Ranka Serventi Seiwerth
Affiliations:
Department of Hematology,University Hospital Center Zagreb,Zagreb,Croatia
Renata Zadro
Affiliations:
Department of Laboratory Diagnostics,University Hospital Center Zagreb,Zagreb,Croatia
EHA Library. Horvat I. May 18, 2017; 181128; E1352
Ms. Ivana Horvat
Ms. Ivana Horvat
Contributions
Abstract

Abstract: E1352

Type: Eposter Presentation

Background
Thrombosis is one of the most frequent events in Ph(-) myeloproliferative neoplasms and the reasons for that are still under investigation.

Aims
The aim of this study was to find out if there is difference in frequency and type of thrombosis in JAK2 V617F positive patients according to their diagnosis, age, sex and V617F allele burden.

Methods
One hundred and eighty two JAK2 V617F positive patients diagnosed with polycythemia vera (PV) N=63, essential thrombocythemia (ET) N=83, and primary myelofibrosis (PMF) N=36 were included in the study. Patients in each group were additionally divided according to sex, age at diagnosis and first thrombosis. V617F allele burden was quantified in peripheral blood granulocyte DNA by real time PCR established by Larsen et al. Br J Haematol 2007;136:745.

Results
Among 182 patients observed, 66 (36%) experienced thrombosis, with arterial thrombosis being twice more frequent than venous thrombosis in all 3 studied groups. In ET group there was statistically significant difference in sex distribution (proportion of females = 0.71), p<0.001. Statistically significant difference in age at diagnosis was observed between ET and PV/PMF patients without thrombosis (p<0.001); the youngest patients were those in ET group. The age at diagnosis of ET patients with thrombosis (65 years, range 23-92) was statistically different compared to ET patients without thrombosis (50 years, range 21-83), p=0.002. Our study showed that V617F allele burden in patients without thrombosis was statistically significantly different between ET (17.2%, range 4.2-55.2) compared to PV (43%, range 1.7-99.9) and PMF (37.1%, range 1.4-99.7), p<0.001. The same statistically significant difference for V617 allele burden was established in patients with thrombosis between ET patients (19%, range 1.4-84.5) and PV and PMF patients (42.5%, range 8.9-97.2 and 48.8%, range 1.6-99.8, respectively), p<0.001.

Conclusion
Our results confirm that arterial thrombosis is more frequent than venous thrombosis in JAK2 V617F positive patients. Female sex was prevalent only in ET group. The age at diagnosis in all studied groups was similar except for ET patients without thrombosis. There was no difference in the frequency and type of thrombosis among ET, PV and PMF patients with high heterogeneity in V617F allele burden between all studied groups regardless of the occurrence of thrombosis.

Session topic: 16. Myeloproliferative neoplasms - Clinical

Keyword(s): Myeloproliferative disorder, mutation analysis, Age, Thrombosis

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies